Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.12 USD
Change Today +0.32 / 3.64%
Volume 118.1K
REPH On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

recro pharma inc (REPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - $9.93
52 Week Low
12/16/14 - $2.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RECRO PHARMA INC (REPH)

Related News

No related news articles were found.

recro pharma inc (REPH) Related Businessweek News

No Related Businessweek News Found

recro pharma inc (REPH) Details

Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, engages in developing non-opioid therapeutics for the treatment of pain. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex to the treatment of chronic pain; and Fadolmidine(Fado) for post-operative and/or neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

5 Employees
Last Reported Date: 03/25/15
Founded in 2007

recro pharma inc (REPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $490.4K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $320.5K
Senior Vice President of Development and Secr...
Total Annual Compensation: $255.2K
Compensation as of Fiscal Year 2014.

recro pharma inc (REPH) Key Developments

Recro Pharma, Inc. Reports Earnings Results for the Fourth Quarter of 2014

Recro Pharma, Inc. reported earnings results for the fourth quarter of 2014. For the period, the company reported a net loss applicable to common shareholders of $3.5 million, or $0.45 per share, compared with a net loss for fourth quarter of 2013 of $496,927, or $3.19 per share. The per-share comparison was skewed by a surge in the number of shares outstanding to 7.7 million from just 155,600. The wider loss came as the company's quarterly research-and-development expenses surged to $2.3 million from $61,896 in the prior-year period. It isn't yet generating revenue.

Alkermes plc, Recro Pharma, Inc. - M&A Call

Recro Pharma to acquire IV/IM Meloxicam and Gainesville, GA GMP Manufacturing facility and business unit from Alkermes

Recro Pharma, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 11:00 AM

Recro Pharma, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 11:00 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Geraldine A. Henwood, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REPH:US $9.12 USD +0.32

REPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation REPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECRO PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at